{
  "abstract": "Patient‐derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with high target specificity, yet their application in organoid systems remains underexplored. Here, we adapted previously described protocols to establish a biobank of prostate cancer (PC) PDOs, achieving a high initial growth success rate (>90%). Histological and molecular analyses confirmed the preservation of key tumor features. Using these models, we assessed several ASOs, with particular emphasis on OGX‐427 (Apatorsen), an ASO targeting heat shock protein 27 (HSP27) that has been evaluated in phase I/II clinical trials. While OGX‐427 effectively suppressed HSP27 expression and inhibited cell growth in 2D cultures, its efficacy was markedly limited in 3D organoids, likely due to extracellular matrix and structural barriers. Removing Matrigel and applying single‐cell transfection overcame these barriers, achieving efficient ASO uptake, significant target protein downregulation, and robust, dose‐dependent inhibition of organoid growth. These findings underscore the utility of PDOs for evaluating ASO‐based therapies and their potential to accelerate precision oncology strategies for PC and other malignancies.",
  "abstract_shown": true,
  "affiliations": [
    "INSERM ERL U1326 CINaM CERIMED CNRS UMR 7325 Aix‐Marseille University Marseille France",
    "Department of Urology Hospital Nord, AP‐HM Aix‐Marseille University Marseille France",
    "Laboratoire d'Anatomie et Cytologie Pathologiques, Hôpital de la Timone, AP‐HM Marseille France",
    "European Center for Research in Medical Imaging (CERIMED) Aix‐Marseille University Marseille France",
    "University of Burgundy Europe, INSERM UMR 1231, HSP‐Pathies Centre for Translational and Molecular Medicine Dijon France",
    "University of Burgundy Europe Centre Georges‐François Leclerc (CGFL) Dijon France",
    "Department of Nuclear Medicine Hôpital de la Timone, AP‐HM, Aix‐Marseille University Marseille France"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Thi Thom Tran"
    },
    {
      "affs": [
        0
      ],
      "name": "Thi Tu Uyen Phan"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Michael Baboudjian"
    },
    {
      "affs": [
        0
      ],
      "name": "Quang Hieu Duong"
    },
    {
      "affs": [
        0
      ],
      "name": "Ines Sousa"
    },
    {
      "affs": [
        0
      ],
      "name": "Thi Thuy Le"
    },
    {
      "affs": [
        0
      ],
      "name": "Virginie Baylot"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Sophie Giusiano"
    },
    {
      "affs": [
        2
      ],
      "name": "Laurent Daniel"
    },
    {
      "affs": [
        3
      ],
      "name": "Pauline Brige"
    },
    {
      "affs": [
        3
      ],
      "name": "Benjamin Guillet"
    },
    {
      "affs": [
        1
      ],
      "name": "Cyrille Bastide"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Carmen Garrido"
    },
    {
      "affs": [
        0,
        6
      ],
      "name": "David Taïeb"
    },
    {
      "affs": [
        0
      ],
      "name": "Thi Khanh Le",
      "orcid": "0000-0003-1883-0371"
    },
    {
      "affs": [
        0
      ],
      "name": "Palma Rocchi",
      "orcid": "0000-0002-4383-4684"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7szf8fr2sxqfc.bib",
  "cited_by": 0,
  "doi": "10.1002/adhm.202505251",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13740942/",
  "id": "7szf8fr2sxqfc",
  "issns": [
    "2192-2640",
    "2192-2659"
  ],
  "landing_url": "https://doi.org/10.1002/adhm.202505251",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "1306|Prostate Cancer Treatment and Research"
    ]
  ],
  "openalex": "W7221477759",
  "pdf_url": null,
  "pmcid": "PMC13740942",
  "pmid": "42860576",
  "published": "2026-10-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7szf8fr2sxqfc.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T12:22:06Z",
      "native_id": "PMC13740942",
      "source": "pmc",
      "url": "https://doi.org/10.1002/adhm.202505251"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:1306|Prostate Cancer Treatment and Research",
      "subfield": "oncology"
    }
  ],
  "title": "Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy",
  "title_text": "Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T12:22:06Z",
  "url": "https://research.draconitic.com/paper/7szf8fr2sxqfc",
  "venue": "Advanced Healthcare Materials",
  "versions": []
}